Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small cell lung cancer.
暂无分享,去创建一个
J. Huse | I. Wistuba | A. Reuben | J. Fujimoto | F. Lang | D. Gibbons | S. Roy-Chowdhuri | C. Haymaker | E. Parra | J. Zhang | H. Kadara | Y. Kudo | D. Duose | H. Dejima | B. Mino | R. Luthra | J.J. Lee | E. Parra | N. Ikeda | L. S. Solis Soto | C. Moran | R. Abraham | A. Vaporcyan | I. Wistuba | J. T. Huse | J. Zhang | F. F. Lang | J. Lee | J. Huse
[1] M. Atkins,et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.
[2] M. Ernst,et al. Targeting Macrophages in Cancer: From Bench to Bedside , 2018, Front. Oncol..
[3] Asha A. Nair,et al. Contraction of T cell richness in lung cancer brain metastases , 2018, Scientific Reports.
[4] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[5] H. Iwata,et al. Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer , 2017, Oncotarget.
[6] F. Aversa,et al. Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value , 2017, Clinical Cancer Research.
[7] S. Lucas,et al. Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies , 2017, Front. Immunol..
[8] Edward F. Chang,et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.
[9] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[10] Zhihong Chen,et al. Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. , 2017, Cancer research.
[11] D. Quail,et al. The Microenvironmental Landscape of Brain Tumors. , 2017, Cancer cell.
[12] C. Brennan,et al. Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. , 2016, Cell reports.
[13] A. Vortmeyer,et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. , 2016, The Lancet. Oncology.
[14] S. Hanash,et al. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer. , 2016, Cancer research.
[15] Jonathan Kipnis,et al. Revisiting the Mechanisms of CNS Immune Privilege. , 2015, Trends in immunology.
[16] Michael Detmar,et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules , 2015 .
[17] Timothy J Keyes,et al. Structural and functional features of central nervous system lymphatics , 2015, Nature.
[18] P. Ellis,et al. Brain metastases in non-small-cell lung cancer. , 2014, Clinical lung cancer.
[19] D. Wong,et al. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis , 2014, BMC Urology.
[20] Rashmi Kanagal-Shamanna,et al. Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. , 2013, The Journal of molecular diagnostics : JMD.
[21] H. Kettenmann,et al. The brain tumor microenvironment , 2011, Glia.
[22] E. Pamer,et al. Monocyte recruitment during infection and inflammation , 2011, Nature Reviews Immunology.
[23] Jinghang Zhang,et al. CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.
[24] D. Hollis,et al. Factors associated with the development of brain metastases , 2010, Cancer.
[25] C. Hunter,et al. Trafficking of immune cells in the central nervous system. , 2010, The Journal of clinical investigation.
[26] F. de Marinis,et al. Multimodality management of non-small cell lung cancer patients with brain metastases , 2010, Current opinion in oncology.
[27] K. Pienta,et al. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. , 2010, Cytokine & growth factor reviews.
[28] S. Lehnardt,et al. Innate immunity and neuroinflammation in the CNS: The role of microglia in Toll‐like receptor‐mediated neuronal injury , 2009, Glia.
[29] Massimo Cristofanilli,et al. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. , 2009, The Journal of surgical research.
[30] R. Figlin,et al. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. , 2009, Cancer research.
[31] L. Carey,et al. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.
[32] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[33] L. D.,et al. Brain tumors , 2005, Psychiatric Quarterly.
[34] Jill S Barnholtz-Sloan,et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Subrata Ghosh,et al. Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.
[36] B. Scheithauer,et al. Microglia in brain tumors , 2002, Glia.
[37] A. Young,et al. Treatment for patients with cerebral metastases. , 1978, Archives of neurology.
[38] A. Fauci,et al. Glucocorticosteroid therapy: mechanisms of action and clinical considerations. , 1976, Annals of internal medicine.